

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/173219 A1

(43) International Publication Date
21 September 2023 (21.09.2023)

(51) International Patent Classification:

A61K 39/395 (2006.01) *C07D 401/10* (2006.01)
A61K 31/454 (2006.01) *C07K 16/30* (2006.01)
A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/CA2023/050344

(22) International Filing Date:

16 March 2023 (16.03.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/320,844 17 March 2022 (17.03.2022) US

(71) Applicant: **CANARIABIO INC.** [KR/KR]; 519, 5 F Eunho Bldg, 29 Jungang-ro, Pyeongtaek-si, Gyeonggi-do 17894 (KR).

(72) Inventor; and

(71) Applicant: **MADIYALAKAN, Ragupathy** [CA/CA]; 9741 - 89 Avenue NW, Edmonton, Alberta T6E 6S4 (CA).

(72) Inventor: **NICODEMUS, Christopher F.**; 706-197 8th Street, Charlestown, Massachusetts 02129 (US).

(74) Agent: **BENOIT & COTE INC.**; 560 Cremazie Blvd. East, Suite 300, Montreal, Québec H2P 1E8 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: USE OF OREGOVOMAB AND PARP INHIBITORS FOR TREATMENT OF OVARIAN CANCER

(57) Abstract: The present document describes a method for improving likelihood of survival in a stage III-IV ovarian cancer patient. The method comprises at least steps of (a) administering daily to a stage III-IV ovarian cancer patient a therapeutically effective dose of Niraparib, for at least 12 weeks; and (b) administering to the patient a therapeutically effective dose of monoclonal antibody mAb-B43.13 during week 1, week 4, week 7, week 12 and week 20 of a treatment period, wherein (a) is performed first and step (b) is performed second, to increase the patient's likelihood of survival in comparison with a control patient who has been diagnosed with stage III-IV ovarian cancer and has received standard of care chemotherapy treatment.

WO 2023/173219 A1